https://www.selleckchem.com/pr....oducts/Vorinostat-sa
40, 95% CI 0.17-0.95]. There was no significant difference in the incidence of all-cause mortality or HHF between the two groups. No significant difference of HR was observed for all-cause mortality (HR = 0.41, 95% CI 0.12-1.41) or HHF (HR = 0.58, 95% CI 0.12-2.81). SGLT2i treatment exhibited benefits for elderly patients with comorbid CHD/T2DM with a lower risk for MACE. SGLT2i treatment exhibited benefits for elderly patients with comorbid CHD/T2DM with a lower risk for MACE. Coronary microembolization (CME) is a complicated p
Like
Comment
Share
